BIBX 1382 in Treating Patients With Solid Tumors

Phase 1

Suspended

• Conditions: Unspecified Adult Solid Tumor, Protocol Specific

• Registration Number: NCT00003980
• Lead Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Brief Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase I trial to study the effectiveness of BIBX 1382 in treating patients who have solid tumors.

Detailed Description

OBJECTIVES: I. Determine the maximum tolerated dose of oral BIBX 1382 in patients with solid tumors. II. Determine qualitative and quantitative toxicities of oral BIBX 1382 in these patients. III. Determine predictability, duration, intensity, onset, reversibility, and dose relationship of the toxicities of oral BIBX 1382 in these patients. IV. Determine safe and optimal doses of oral BIBX 1382 for a Phase II study. V. Assess the pharmacokinetics of oral BIBX 1382 in these patients. VI. Document any antitumor activity in these patients treated with oral BIBX 1382.

OUTLINE: This is a dose escalation study. Patients receive BIBX 1382 IV over 1 hour followed 7 days later by oral BIBX 1382. Beginning 3 days later, patients receive oral BIBX 1382 daily for 28 days. Courses of daily oral BIBX 1382 repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of oral BIBX 1382. The maximum tolerated dose (MTD) is defined as the dose at which dose limiting toxicity occurs in at least 2 of 6 patients. Patients are followed for up to 4 weeks.

PROJECTED ACCRUAL: A total of 40-80 patients will be accrued for this study over 18 months.

Study Timeline

• Study Start: 1999-02
• Study First Submitted: 1999-11-01
• Study First Submitted QC: 2004-05-24
• Study First Posted: 2004-05-25
• Status Verified: 2012-07
• Last Update Submitted: 2012-07-10
• Last Update Posted: 2012-07-11

Recruitment & Eligibility

• Status: SUSPENDED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (27)

University Hospital; 🇨🇭 Basel, Switzerland

Kantonsspital - Saint Gallen; 🇨🇭 Saint Gallen, Switzerland

Innsbruck Universitaetsklinik; 🇦🇹 Innsbruck, Austria

Newcastle General Hospital; 🇬🇧 Newcastle Upon Tyne, England, United Kingdom

C.R.C. Beatson Laboratories; 🇬🇧 Glasgow, Scotland, United Kingdom

Ninewells Hospital and Medical School; 🇬🇧 Dundee, Scotland, United Kingdom

Inselspital, Bern; 🇨🇭 Bern, Switzerland

Centre Leon Berard; 🇫🇷 Lyon, France

Klinikum Nurnberg; 🇩🇪 Nuremberg (Nurnberg), Germany

Kaiser Franz Josef Hospital; 🇦🇹 Vienna, Austria

Institut Jules Bordet; 🇧🇪 Brussels, Belgium

Ludwig Institute for Cancer Research-Brussels Branch; 🇧🇪 Brussels, Belgium

Universitair Ziekenhuis Antwerpen; 🇧🇪 Edegem, Belgium

U.Z. Gasthuisberg; 🇧🇪 Leuven, Belgium

Herlev Hospital - University Hospital of Copenhagen; 🇩🇰 Herlev, Denmark

Institut Claudius Regaud; 🇫🇷 Toulouse, France

Institut Gustave Roussy; 🇫🇷 Villejuif, France

Antoni van Leeuwenhoekhuis; 🇳🇱 Amsterdam, Netherlands

Rotterdam Cancer Institute; 🇳🇱 Rotterdam, Netherlands

Academisch Ziekenhuis der Vrije Universiteit; 🇳🇱 Amsterdam, Netherlands

Academisch Ziekenhuis Groningen; 🇳🇱 Groningen, Netherlands

University Medical Center Nijmegen; 🇳🇱 Nijmegen, Netherlands

Western General Hospital; 🇬🇧 Edinburgh, Scotland, United Kingdom

Norwegian Radium Hospital; 🇳🇴 Oslo, Norway

CRLCC Nantes - Atlantique; 🇫🇷 Nantes-Saint Herblain, France

Universitaetsklinik und Strahlenklinik - Essen; 🇩🇪 Essen, Germany

Centre Jean Perrin; 🇫🇷 Clermont-Ferrand, France